Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Abbott (ABT) Up 5.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal second-quarter performance.
QIAGEN (QGEN) Expands Sample Technologies Line With New Launch
by Zacks Equity Research
QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.
Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.
Abbott (ABT) Just Overtook the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
If You Invested $1000 in Abbott a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Here's Why You Should Retain Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.
Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure
by Zacks Equity Research
Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Charles River (CRL) to Advance AI Drug Discovery With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) strength in Health Care Benefits business arm and stable solvency position.
Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service
by Zacks Equity Research
Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.
Hologic's (HOLX) Q4 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Solid year-over-year growth in the Breast Health segment drives Hologic's (HOLX) Q4 performance.
BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX), led by growing demand for WATCHMAN FLX devices and upbeat guidance.
Alcon (ALC) Unveils New Progress in Presbyopia Correcting IOLs
by Zacks Equity Research
Alcon's (ALC) Clareon Vivity IOL highlights proven results and high levels of patient satisfaction. It will offer a similar halo profile compared with a monofocal IOL.
Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.
Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the third quarter.
Wall Street Analysts See a 25.28% Upside in Abbott (ABT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 25.3% upside potential for Abbott (ABT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y
by Zacks Equity Research
Despite higher international business-to-business sales and rental revenues, Inogen's (INGN) overall third-quarter results reflect soft performances.
Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.
Charles River's (CRL) Q3 Earnings Beat, Margins Decline
by Zacks Equity Research
Charles River's (CRL) RMS organic revenue growth is primarily driven by research model services, particularly the Insourcing Solutions business.
DaVita (DVA) Q3 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its third-quarter performance.
Masimo (MASI) Q3 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Masimo's (MASI) overall third-quarter results reflect soft performance despite strength in the Hearables category.
Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.